Benjamin Halladay Sells Shares of ESPR $ESPR
Key Points
- Benjamin Halladay sold 10,773 shares of Esperion Therapeutics, Inc. Common Stock ($ESPR) worth $34,042.68.
- $ESPR last traded around $3.17.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Benjamin Halladay, Chief Financial Officer at Esperion Therapeutics, Inc. Common Stock ($ESPR), sold 10,773 shares at an average price of $3.16, for a total transaction of $34,042.68. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Esperion Therapeutics, Inc. Common Stock Stock Price
Shares of Esperion Therapeutics, Inc. Common Stock ($ESPR) traded around $3.17 on Thursday.
Esperion Therapeutics, Inc. Common Stock Earnings
Analysts Set New Price Targets
About Esperion Therapeutics, Inc. Common Stock
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. As of July 13, 2026, Esperion Therapeutics, Inc. was taken private.
Get Esperion Therapeutics, Inc. Common Stock alerts
New 13F filings, insider trades, and analyst moves on $ESPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.